koko体育app

欢迎来到《koko体育app 学报（医学版）》
贾合磊, 卢长青, 王娟等. shRNA干扰NLRP3对晚期糖基化终末产物诱导的心肌细胞炎症反应的影响[J]. koko体育app 学报（医学版）, 2019, 50(1): 7-12. DOI:
引用本文: 贾合磊, 卢长青, 王娟等. shRNA干扰NLRP3对晚期糖基化终末产物诱导的心肌细胞炎症反应的影响[J]. koko体育app 学报（医学版）, 2019, 50(1): 7-12. DOI:
JIA He-lei, LU Chang-qing, WANG Juan. et al. The Effect of Interference of NLRP3 with shRNA on AGEs-induced Inflammatory Response in Myocardial Cell[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(1): 7-12. DOI:
Citation: 🅷 JIA He-lei, LU Chang-qing, WANG Juan. et al. The Effect of Interference of NLRP3 with shRNA on AGEs-induced Inflammatory Response in Myocardial Cell[J]. Journal of Sichuan University (Medical Sciences), 2019, 50(1): 7-12. DOI:

shRNA干扰NLRP3对晚期糖基化终末产物诱导的心肌细胞炎症反应的影响

The Effect of Interference of NLRP3 with shRNA on AGEs-induced Inflammatory Response in Myocardial Cell

  • 摘要: 目的  探讨沉默NOD 样受体家族pyrin域3 (NOD-like receptor family,pyrin domain containing 3, NLRP3)炎性小体对晚期糖基化终末产物(advanced glycation end products, AGEs)诱导的心肌细胞损伤的调节作用及机制。 方法  H9c2心肌细胞分为4组：对照组、 AGEs组、AGEs+sh-Ctrl组、 AGEs+sh-NLRP3组，后两组细胞首先将短发夹RNA（shRNA）对照（sh-Ctrl）和shRNA干扰NLRP3（sh-NLRP3）质粒分别转染入H9c2细胞，然后后3组细胞用100 mg/L AGEs处理24 h，建立H9c2损伤模型，对照组细胞用溶剂处理24 h。Western blot检测NLRP3、凋亡相关微粒蛋白(apoptosis-associated speck-like protein containing CARD, ASC)、 Caspase-3、 Caspase-9、核转录因子κB(nuclear factor κB, NF-κB) P65和磷酸化P65（p-P65）的表达，酶联免疫吸附实验(ELISA)检测白细胞介素(interleukin, IL)-6、IL-18和IL-1β的水平，流式细胞术检测细胞凋亡，免疫荧光染色检测细胞核中NF-κB P65的水平。结果  AGEs组和AGEs+sh-Ctrl组NLRP3、 ASC、Caspase-3和Caspase-9的表达均高于对照组( P<0.05)。与AGEs组相比，AGEs+sh-NLRP3组NLRP3、ASC、Caspase-3和Caspase-9的表达均下降( P<0.05)。与对照组相比，AGEs组和AGEs+sh-Ctrl组IL-6、IL-18、IL-1β水平升高，细胞凋亡率上升(P<0.05)。AGEs+sh-NLRP3组IL-6、IL-18、IL-1β水平和细胞凋亡率低于AGEs组( P<0.05)。AGEs组和AGEs+sh-Ctrl组NF-κB P65磷酸化水平及细胞核的NF-κB P65水平高于对照组(P<0.05)。与AGEs组相比，AGEs+sh-NLRP3组NF-κB P65磷酸化水平及细胞核的NF-κB P65水平降低( P<0.05)。结论  沉默NLRP3可通过抑制NF-κB P65的活化减轻AGEs诱导的心肌细胞凋亡及炎症反应。  
    Abstract: Objective  This study aims to explore the effect of silence of NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome on advanced glycation end products (AGEs)-induced myocardial injury. Methods  The myocardial injury model was indued by AGEs. NLRP3 was silenced by shRNA. H9c2 cells were divided into four groups: H9c2 (control group); AGEs group; AGEs+sh-Ctrl group; AGEs+sh-NLRP3 group. The latter two groups of cells will first shRNA control （sh-Ctrl） and shRNA-NLRP3 （sh-NLRP3） plasmids were transfected into H9c2 cells, the last 3 cells were then treated for 24 h with 100 mg/L AGEs, establishment of H9c2 damage model, control cells were treated with solvent for 24 h; Apoptosis was measured by Hoechst33258 staining. The levels of interleukin (IL)-6, IL-18 and IL-1β were detected by enzyme-linked immunosorbent assay (ELISA). The protein levels of NLRP3, apoptosis-associated speck-like protein containing CARD (ASC), Caspase-3, Caspase-9, nuclear factor κB (NF-κB) P65 and p-P65 were tested by Western blot. The nuclear NF-κB P65 levels were detected by immunofluorescent staining. Results  The expressions of NLRP3, ASC, Caspase-3 and Caspase-9 in AGEs group and AGEs+sh-Ctrl group was higher than control group ( P<0.05). Compared with AGEs group, the expressions of NLRP3, ASC, Caspase-3 and Caspase-9 in AGEs+sh-NLRP3 group was decreased ( P<0.05). Compared with control group, the apoptosis and the levels of IL-6, IL-18 and IL-1β in AGEs group and AGEs+sh-Ctrl group were elevated (P<0.05). The apoptosis and the levels of IL-6, IL-18 and IL-1β in AGEs+sh-NLRP3 group were lower than those of AGEs group ( P<0.05). The phosphorylation of NF-κB P65 and nuclear NF-κB P65 in AGEs group and AGEs+sh-Ctrl group were higher than control group (P<0.05). Compared with AGEs group, the phosphorylation of NF-κB P65 and nuclear NF-κB P65 in AGEs+sh-NLRP3 group were reduced ( P<0.05). Conlusion  Silence of NLRP3 inflammasome alleviates AGEs-induced apoptosis and inflammatory response in myocardial cell via inhibiting NF-κB P65 activation.  
    • HTML全文
© 2019 《koko体育app 学报（医学版）》编辑部　版权所有 cc

开放获取♒ 本文遵循知识共享署名—非商业性使用4.0国际许可协议（CC BY-NC 4.0），允许第三方对本刊发表的论文自由共享（即在任何媒介以任何形式复制、发行原文）、演绎（即修改、转换或以原文为基础进行创作），必须给出适当的署名，提供指向本文许可协议的链接，同时标明是否对原文作了修改；不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问

/

返回文章
返回
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"}); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!